Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 1 4Phase EARLY_PHASE1 2Phase 1/2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 2Depression 1Anxiety Disorders 1

Interventions

Magnetic Resonance Spectroscopy 59Cyclophosphamide 44pembrolizumab 34Radiotherapy 30fludarabine 27Nivolumab 26Biopsy 26Metformin 22Fluorodeoxyglucose F18 22Specimen Handling 20Bevacizumab 20Temozolomide 17Radiosurgery 17Cisplatin 16Carboplatin 14Fluorouracil 13Dexamethasone 13Paclitaxel 12Gemcitabine 12Etoposide 12gallium 68 PSMA-11 11durvalumab 11X-Rays 11Surgical Procedures, Operative 11Radiation 11Positron Emission Tomography Computed Tomography 11Letrozole 11Irinotecan 11Ipilimumab 11Surveys and Questionnaires 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × OTHER × Psilocybin × Clear all
NCT04522804 2024-03-20

HOPE

University of Utah

Phase EARLY_PHASE1 Completed
12 enrolled
Tumor-Agnostic

Neoplasms

NCT00957359 2020-10-20

Psilocybin Cancer Anxiety Study

NYU Langone Health

Phase EARLY_PHASE1 Completed
29 enrolled 59 charts

Anxiety Disorders, Depression, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡